UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
ISOLYSER COMPANY, INC.
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
(Title of Class of Securities)
464888-10-6
(CUSIP Number)
Stephen D. Fox, 1201 West Peachtree Street, Suite 2800,
Atlanta, Georgia 30309-3450 (404) 873-8528
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
AUGUST 30, 1996
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule
13d-1(b)(3) or (4), check the following box. / /
Check the following box if a fee is being paid with the statement.
/ / (A fee is not required only if the reporting person: (1) has
a previous statement on file reporting beneficial ownership of more
than five percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto reporting
beneficial ownership of five percent or less of such class.) (See
Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should
be filed with the Commission. See Rule 13d-1(a) for other parties
to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in
a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
SCHEDULE 13D
- -------------------------------------------------------------------
1 Name of Reporting Person SS. or I.R.S. Identification No. of
Above Person
Microtek Medical, Inc.
- ------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group
(a) / /
(b) / /
- -------------------------------------------------------------------
3 SEC Use Only
- ------------------------------------------------------------------
4 Source of Funds
00
- ------------------------------------------------------------------
5 Check Box if Disclosure of Legal Proceedings is Required
Pursuant to Items 2(d) or 2(E)
/ /
- -------------------------------------------------------------------
6 Citizenship or Place of Organization
Delaware
- ------------------------------------------------------------------
Number of 7 Sole Voting Power 0
shares beneficially
owned by each 8 Shared Voting Power 0
reporting person
with 9 Sole Dispositive Power 0
10 Shared Dispositive Power 0
11 Aggregate Amount Beneficially Owned by Each Reporting Person
- -------------------------------------------------------------------
0
- ------------------------------------------------------------------
12 Check Box if the Aggregate Amount in Row (11) Excludes
Certain Shares / /
- -------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11)
0%
- -------------------------------------------------------------------
14 Type of Reporting Person
CO
- ------------------------------------------------------------------
SEE INSTRUCTIONS BEFORE FILLING OUT!
Items 4 and 5(e) are amended as set forth below. All other items
remain unchanged.
ITEM 4. PURPOSE OF TRANSACTION.
On August 30, 1996, Isolyser Company, Inc. (the "Company")
acquired all of the outstanding securities of Microtek Medical,
Inc. ("Microtek") pursuant to a merger (the "Merger"), and Microtek
became a wholly-owned subsidiary of the Company. The proxies (the
"Proxies") previously granted to Microtek by Messrs. Robert L.
Taylor and Travis W. Honeycutt to vote an aggregate of 6,028,872
shares of Company Common Stock pertained only to the Company's
shareholder meeting held with respect to the Merger. Since this
meeting was held on August 30, 1996, the Proxies have no further
effect or validity, and Microtek hereby files this Amendment No. 1
to Schedule 13D to reflect the fact that it no longer beneficially
owns any of the Company's securities.
ITEM 5(e). August 30, 1996.
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
MICROTEK MEDICAL, INC.
By: Kimber L. Vought
__________________________
Kimber L. Vought
President and Chief Executive Officer Date: August 30, 1996
